PFE  Pfizer Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

183.1B

Vuru Grade

76.12/100

Current Price

$28.88
-0.015 (-0.05%)

Growth Price

$30.44
Undervalued by 5.43%

Stability Price

$11.60
Overvalued by 59.84%

Company Metrics

  • 18.15 P/E
  • 3.64 P/S
  • 2.39 P/B
  • 1.592 EPS
  • 11.61% Cash ROIC
  • 1.39 Cash Ratio
  • 1.02 / 3.53% Dividend
  • 23.55M Avg. Vol.
  • 6.34B Shares
  • 183.1B Market Cap.

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

3 Reasons Pfizer Inc.'s Stock Could Rise
Motley Fool - Aug 19, 2014
Pfizer (NYSE: PFE ) , arguably the preeminent pharmaceutical company in the world, continues to pump out billions in free cash flow annually, deliver delectable gross margins, and pay out an annual dividend that puts the S&P 500 average yield of 2% to ...
Pfizer Continues Search For Inversion Deal: Might Pursue Actavis, GSK Or Valeant
Bidness Etc - 12 hours ago
Pfizer Inc. (PFE) is actively looking for non-US companies as acquisition targets in order to benefit from tax inversion. Pfizer has over $30 billion in offshore cash that it would be able to access without paying taxes, if it shifts its US domicile to ...
AstraZeneca plc (AZN) Acquisition: Hard Nut to Crack for Pfizer Inc. (PFE) - StockWise Daily
Pfizer Inc (NYSE:PFE) Bids Again For AstraZeneca plc (NYSE:AZN) - Stocks.org
Pfizer Might Bid Again For AstraZeneca
Bidness Etc - 14 hours ago
Pfizer Inc. (PFE) is still trying to pursue an acquisition deal with the London-based AstraZeneca plc (ADR) (AZN) to bring about down its tax costs and take on a new product line of drugs.
Pfizer Files NDA For Breast Cancer Drug
Bidness Etc - Aug 18, 2014
Pfizer Inc. (PFE) reported today that its new drug application (NDA) for Palbociclib to the Food and Drug Administration (FDA) is complete.
Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib - WallStreetPR
Pfizer submits anti-breast cancer drug for FDA approval - New Haven Register
5 Things Pfizer Inc.'s Management Wants You to Know
Motley Fool - Aug 12, 2014
For the quarter, Pfizer reported that revenue slipped 2%, or $200 million, to $12.77 billion. Profits were also a mixed tale with Pfizer's adjusted income dipping 6% and its adjusted EPS rising 4%. The company also lowered its full-year revenue ...
Pfizer Inc. (PFE): Trouble Ahead For The Stock - ETF Daily News
Intel Corporation (NASDAQ:INTC), Pfizer Inc. (NYSE:PFE), Microsoft Corporation ... - US Trade Media
Pfizer: Continuing The Search For Tax Inversion
Bidness Etc - Aug 15, 2014
The next big pharmaceutical company that might be making a move to relocate out of the US for tax benefits could be Pfizer Inc. (PFE). The idea behind tax inversion deals is to acquire companies in countries where the tax rate is lower than the US. In ...
Investors sent on a wild ride by hostile deals - MarketWatch
Pfizer Inc. (PFE) Tops DJIA Gainers for August 14
Equities.com - Aug 14, 2014
The Dow closed at 16,713.60 on Thursday, which is a 0.37% move from yesterday's close. Pfizer Inc. led all gainers with a 1.84% jump.
Pfizer Megadeal Still in Sight After Astra: Real M&A
Bloomberg - Aug 5, 2014
After being rejected by AstraZeneca Plc (AZN), Pfizer Inc. (PFE) still has a chance to clinch the drug industry's biggest deal.
Pfizer Partners With 23andMe To Research Bowel Disease
Bidness Etc - Aug 13, 2014
Pfizer Inc. (PFE) is planning to join hands with genetics testing company 23andMe to explore the role of genetics in a patient's likelihood of contracting inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis.
23andMe Announces Agreement with Pfizer Inc. to Research Genetics of ... - MarketWatch
Pfizer, 23andMe Team up to Study Bowel Disease - ABC News
Pfizer Faces Surge In Lawsuits Over Cholesterol Drug Lipitor
Bidness Etc - Aug 11, 2014
Pfizer Inc. (PFE) is facing an increasing number of lawsuits related to its anti-cholesterol drug Lipitor from women who accuse the company of deliberately withholding information about side effects pertaining to use of the drug.
How Will Pfizer (PFE) Stock React As Lawsuits Over Lipitor Grow? - TheStreet.com
Pfizer Inc. (NYSE:PFE) Facing Sharp Sword Of Surging Lipitor-Related Lawsuits ... - WallStreetPR